TY - JOUR
T1 - Complement inhibitors as therapeutic agents
AU - Liszewski, M. Kathryn
AU - Subramanian, V. Bala
AU - Atkinson, John P.
N1 - Funding Information:
This work was supported by funding from the National Institutes of Health (1 RO1 A141592 and 5 RO1 A137618) and front CytoMed, Inc., Cambridge, MA. J.P Atkinson and Washington University have a financial interest in CytoMed, Inc.
Funding Information:
Work from the author's laboratory presented here was supported by grants from the Arthritis Foundation, American Heart Association and NIH AI#41090. In addition to contributing to the work reviewed here, the author wishes to thank Ron Nepomuceno and Sol Ruiz for helping to prepare the figures presented.
PY - 1997/12
Y1 - 1997/12
N2 - This report has described several currently evolving strategies and therapeutic agents designed to inhibit the complement system. Many others can be envisioned. Analagous to the utility of therapeutic agents that inhibit the coagulation cascade, it can be anticipated that complement inhibitors will find an important niche in our armamentarium of drugs to reduce undesirable inflammatory reactions.
AB - This report has described several currently evolving strategies and therapeutic agents designed to inhibit the complement system. Many others can be envisioned. Analagous to the utility of therapeutic agents that inhibit the coagulation cascade, it can be anticipated that complement inhibitors will find an important niche in our armamentarium of drugs to reduce undesirable inflammatory reactions.
UR - http://www.scopus.com/inward/record.url?scp=0007823453&partnerID=8YFLogxK
U2 - 10.1016/s0197-1859(00)80025-4
DO - 10.1016/s0197-1859(00)80025-4
M3 - Article
AN - SCOPUS:0007823453
VL - 17
SP - 168
EP - 173
JO - Clinical Immunology Newsletter
JF - Clinical Immunology Newsletter
SN - 0197-1859
IS - 12
ER -